Literature DB >> 23746475

The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.

Stephen T Wrobleski1, Shuqun Lin, T G Murali Dhar, Alaric J Dyckman, Tianle Li, Sidney Pitt, Rosemary Zhang, Yi Fan, Arthur M Doweyko, John S Tokarski, Kevin F Kish, Susan E Kiefer, John S Sack, John A Newitt, Mark R Witmer, Murray McKinnon, Joel C Barrish, John H Dodd, Gary L Schieven, Katerina Leftheris.   

Abstract

A novel series of p38 MAP kinase inhibitors with high selectivity for the p38α isoform over the other family members including the highly homologous p38β isoform has been identified. X-ray co-crystallographic studies have revealed an unprecedented kinase binding mode in p38α for representative analogs, 5c and 9d, in which a Leu108/Met109 peptide flip occurs within the p38α hinge region. Based on these findings, a general strategy for the rational design of additional promising p38α isoform selective inhibitors by targeting this novel binding mode is proposed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746475     DOI: 10.1016/j.bmcl.2013.05.047

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors.

Authors:  Johan J N Veerman; Yorik B Bruseker; Eddy Damen; Erik H Heijne; Wendy van Bruggen; Koen F W Hekking; Rob Winkel; Christopher D Hupp; Anthony D Keefe; Julie Liu; Heather A Thomson; Ying Zhang; John W Cuozzo; Andrew J McRiner; Mark J Mulvihill; Peter van Rijnsbergen; Birgit Zech; Louis M Renzetti; Lee Babiss; Gerhard Müller
Journal:  ACS Med Chem Lett       Date:  2021-03-03       Impact factor: 4.345

2.  Network Pharmacology-Based Analysis of the Underlying Mechanism of Huajiao for Pain Relief.

Authors:  Mingquan Wu; Hong-Ling Du; Xu Zhou; Wei Peng; Limei Liu; Zhong Zhang; He Tu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-04       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.